
    
      A phase 1b, pilot study to evaluate the safety, tolerability and antiviral activity of oral
      ACH-0143102 administered in combination with ribavirin for 12 weeks in treatment naive
      subjects with chronic hepatitis C virus infection genotype 1b.
    
  